Two hormones, one injection: how CagriSema attacks obesity from both sides
Every obesity drug on the market right now targets a single hormonal pathway. Wegovy and Ozempic mimic GLP-1. Zepbound and Mounjaro mimic GLP-1 and GIP. CagriSema takes a different approach entirely: it pairs semaglutide (the same GLP-1 receptor agonist in Wegovy) with cagrilintide, a long-acting analog of a hormone called amylin. The result is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, delivered as a single once-weekly subcutaneous injection. If approved, it would become the first injectable GLP-1 and amylin combination treatment available.
To understand why adding amylin matters, think of appetite regulation like a stereo system with two speakers. GLP-1 drugs turn down one speaker -- they slow gastric emptying, signal fullness from the gut, and reduce reward-driven eating. Amylin turns down the other speaker through a partially separate set of brain circuits. According to a 2025 review in Diabetes Therapy by Volcansek and colleagues, amylin is a neuroendocrine hormone co-secreted with insulin from pancreatic beta cells that suppresses glucagon secretion, delays gastric emptying, and promotes satiety by binding to receptors in the area postrema and hypothalamic nuclei -- brain regions that govern both homeostatic hunger and hedonic (pleasure-driven) eating.
The key word is "additive." GLP-1 and amylin act through what researchers describe as "distinct and overlapping neural satiety and reward pathways". They both suppress appetite, but they do so through partially different mechanisms, which means combining them produces more total appetite suppression than either one alone. Early clinical data backed this up: in a phase 1b trial, semaglutide plus cagrilintide 2.4 mg produced 17.1% weight loss at just 20 weeks, compared to 9.8% with semaglutide plus placebo.
There may be another advantage that does not show up clearly in weight-on-a-scale numbers. Dr. Melanie Davies, lead investigator on the CagriSema diabetes trials and co-director of the Leicester Diabetes Centre, told Reuters that amylin has been shown in animal studies to boost energy expenditure, and that if the same effect is confirmed in humans, "amylin would have an advantage, as you would preferentially lose fat and preserve lean mass." That finding remains preliminary -- REDEFINE 8, a 104-week trial specifically measuring body composition, has not yet reported results -- but it speaks to why amylin biology is attracting serious pharmaceutical investment beyond Novo Nordisk.
For patients, the practical difference is straightforward: CagriSema is one injection, once a week, combining two drugs that were previously only available separately or not at all. The amylin component is not available as a standalone long-acting weight-loss drug anywhere in the world. The only approved amylin-based medication is pramlintide (Symlin), a short-acting version that requires injection with every meal and is approved only as an adjunct to insulin therapy. CagriSema brings a different hormonal pathway altogether into the obesity treatment toolkit, in a form factor patients are already familiar with.
22.7% weight loss in 68 weeks: what REDEFINE-1 found
REDEFINE-1 was the trial that put CagriSema on the map -- and the one that confused investors who read the headline number without understanding the context beneath it. Published in the New England Journal of Medicine and presented at the American Diabetes Association meeting in Chicago, it was a 68-week, phase 3a, multicenter, double-blind, placebo-controlled and active-controlled trial enrolling 3,417 adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication.
The trial had four arms: 2,108 participants received CagriSema, 302 received semaglutide alone, 302 received cagrilintide alone, and 705 received placebo. All groups received lifestyle interventions. That 21:3:3:7 randomization ratio was deliberate -- the large CagriSema arm was designed to generate robust safety data, while the monotherapy arms provided mechanistic context.
Two different statistical approaches produced two different headline numbers, and this is where the confusion starts. The treatment-policy estimand (essentially an intention-to-treat analysis that counts everyone regardless of whether they stayed on the drug) showed CagriSema produced 20.4% weight loss versus 3.0% with placebo -- a difference of 17.3 percentage points (95% CI: -18.1 to -16.6, P<0.001). The trial-product estimand (which estimates what would have happened if everyone had stayed on treatment) showed 22.7% weight loss for CagriSema versus 2.3% for placebo.
The monotherapy arms tell a story that often gets buried in headlines. On the trial-product estimand, semaglutide alone produced 16.1% weight loss, and cagrilintide alone produced 11.8%. CagriSema's 22.7% represents a 6.6 percentage-point improvement over the best-performing GLP-1 monotherapy. That gap is what makes the amylin component clinically meaningful -- it is not a marginal add-on.
The responder analysis: 91.9% of CagriSema patients lost at least 5% of their body weight (vs 31.5% placebo). More strikingly, 54% of participants who started with obesity-level BMI crossed below the BMI 30 threshold by week 68 -- meaning they no longer qualified as obese by clinical definition. In the placebo group, only 11.1% reached that threshold. And 40.4% of CagriSema patients lost more than 25% of their body weight, compared to 16.2% on semaglutide alone.
REDEFINE-1 also revealed benefits beyond the scale. A secondary analysis published separately found that CagriSema reduced systolic blood pressure by 10.9 mmHg compared to 2.8 mmHg with placebo, and 63% of CagriSema patients reached blood pressure targets versus 32% on placebo. Among the 167 participants with resistant hypertension at baseline, 42% on CagriSema reached blood pressure targets. Perhaps most telling: 39.6% of CagriSema patients who were taking blood pressure medication were able to decrease or stop those medications by week 68, compared to 18.8% on placebo.
For patients with type 2 diabetes, the REDEFINE-2 trial (a separate 68-week study of 1,206 participants) showed that 73.5% of CagriSema patients achieved an HbA1c of 6.5% or below, versus 15.9% on placebo. People with diabetes typically lose less weight on GLP-1 drugs than those without, so the 15.7% weight loss seen in REDEFINE-2 should be evaluated in that context rather than compared directly to REDEFINE-1's numbers.
The stock crashed 50%. The drug works fine.
When Novo Nordisk disclosed REDEFINE-1 results in December 2024, the on-treatment weight loss came in at 22.7% -- below the 25% threshold Novo's own executives had publicly targeted. The market reaction was swift: Novo's stock fell roughly 50% from its 2024 highs. By February 2026, after the REDEFINE-4 head-to-head comparison with tirzepatide showed CagriSema also could not match Eli Lilly's drug, shares were 72% off record highs set in mid-2024. Emily Field, head of European pharmaceuticals research at Barclays, told CNBC that "sentiment toward these guys is as negative as it's ever been."
Here is why the "disappointment" narrative deserves scrutiny.
The 25% target was a company-set expectation, not a clinical benchmark. No regulatory agency requires a drug to hit 25% weight loss to be approved or considered effective. CagriSema's 20.4% on the ITT analysis is the number that will appear on a drug label, and as Novo's R&D chief Martin Holst Lange pointed out, that figure is "roughly in line with what's on Zepbound's prescribing information." The gap between clinical reality and investor expectation was set by Novo's own guidance, not by scientific failure.
The trial design itself may explain part of the gap. REDEFINE-1 used a flexible dosing protocol that allowed patients to stay on lower doses if they experienced tolerability issues. A 2025 review in Diabetes Therapy noted that this flexible dosing protocol could have accounted for not meeting the 25% body weight reduction target. Dr. Melanie Davies, the lead investigator, offered a counterintuitive finding: "Those patients on lower doses actually had higher weight loss reduction." Patients who stayed on lower doses tolerated the drug better, stayed on it longer, and lost more weight than those who were forced up to maximum dose and then dropped out. "We feel that flexible dosing is a positive for patients," she said.
Consider the comparison that actually matters for patients: CagriSema produced 6.6 percentage points more weight loss than semaglutide (Wegovy) alone. That is the therapeutic question -- does adding amylin to an existing GLP-1 drug produce meaningfully better outcomes? The answer from REDEFINE-1 is unambiguously yes. Barclays' Emily Field herself acknowledged the disconnect: "The stock reaction felt disproportionate, but there's just no buyers that are offsetting the sellers."
Novo's CEO Mike Doustdar was blunt about the narrative: "To say it's obsolete is quite belittling a fantastic drug, in all honesty." He pointed to the 23% on-treatment weight loss from REDEFINE-4 as evidence that CagriSema offers "clinically meaningful additive weight loss effects" beyond GLP-1 biology alone. He also called the 25.5% tirzepatide result in that same head-to-head trial "an abnormality" not replicated in other studies.
Where CagriSema fits in the next-generation weight loss arms race
The obesity drug market is no longer a two-horse race between Novo Nordisk and Eli Lilly. It is a crowded field where several distinct pharmacological approaches are competing for what analysts estimate will be a market worth upwards of $100 billion by 2030. Here is how CagriSema stacks up.
| Drug | Mechanism | Weight Loss (on-treatment) | Trial Duration | Status |
|---|---|---|---|---|
| CagriSema (Novo Nordisk) | GLP-1 + amylin | 22.7% (REDEFINE-1, 68 wk) | 68 weeks | NDA filed Dec 2025 |
| Tirzepatide / Zepbound (Eli Lilly) | GLP-1 + GIP | ~22% (SURMOUNT trials) | 72 weeks | Approved |
| Semaglutide / Wegovy (Novo Nordisk) | GLP-1 | 15-16% | 68 weeks | Approved |
| Retatrutide (Eli Lilly) | GLP-1 + GIP + glucagon | ~24% (phase 2) | 48 weeks | Phase 3 |
The REDEFINE-4 head-to-head trial delivered the most direct comparison available. Over 84 weeks, CagriSema produced 23.0% weight loss versus tirzepatide 15 mg at 25.5% on the efficacy estimand. The treatment-regimen estimand showed 20.2% versus 23.6%. CagriSema did not meet the primary endpoint of non-inferiority.
Those numbers tell a less damning story than headlines suggest. Dr. Davies told Reuters that CagriSema's phase 3 results "compared very favorably also with what we've seen with tirzepatide, which was previously the best-in-class." She was referring to tirzepatide's own pivotal trials (SURMOUNT), where the drug produced 22% weight loss -- notably less than the 25.5% it achieved when tested against CagriSema in REDEFINE-4. Cross-trial comparisons are always imperfect, but the discrepancy is worth noting.
The competition extends beyond Eli Lilly. Tirzepatide targets GLP-1 and GIP receptors -- a dual-agonist approach that differs from CagriSema's GLP-1 plus amylin combination. Retatrutide, also from Lilly, targets three receptors (GLP-1, GIP, and glucagon) and showed roughly 24% weight loss in a phase 2 trial at 48 weeks, though phase 3 data is still pending. Swiss pharmaceutical giant Roche struck a deal worth up to $5.3 billion to develop Zealand Pharma's petrelintide, another amylin analog, though that drug is not expected to reach market until around 2030. AstraZeneca's AZD6234, a selective amylin receptor agonist with a focus on fat-selective weight loss, is in phase 2 trials.
The emerging picture is not winner-take-all. Different mechanisms may suit different patients. Soren Lontoft, pharma equity analyst at Sydbank, told CNBC that "It's about addressing different needs in this market." A patient who does not respond well to GLP-1/GIP dual agonism might respond differently to GLP-1/amylin. And if amylin's potential to preserve lean mass while preferentially reducing fat is confirmed in ongoing body composition studies, CagriSema could occupy a distinct clinical niche that pure weight-loss numbers do not capture.
From NDA to pharmacy shelf: when patients might get CagriSema
Novo Nordisk submitted a New Drug Application (NDA) to the FDA on December 18, 2025, based on data from both REDEFINE-1 and REDEFINE-2. The application covers once-weekly CagriSema for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity, to be used alongside a reduced-calorie diet and increased physical activity.
The FDA typically takes 10 to 12 months to review a standard NDA, which puts a decision in late 2026. Martin Holst Lange, Novo's head of development, told Reuters he expects approval "maybe around the beginning of 2027." CNBC's reporting suggests the drug could launch by end of 2026 or early 2027 depending on the review timeline.
| Milestone | Expected Timeline |
|---|---|
| NDA submitted to FDA | December 18, 2025 (completed) |
| FDA decision (PDUFA date) | Late 2026 |
| Potential U.S. launch | Late 2026 to early 2027 |
| REDEFINE 11 data (extended duration) | First half 2027 |
| Higher-dose CagriSema phase 3 trial start | Second half 2026 |
| REDEFINE 3 (cardiovascular outcomes) | Ongoing (event-driven, 7,000 patients) |
The pipeline beyond the initial approval matters. Novo Nordisk is running the REDEFINE 11 trial, an 80-week study of 600 adults with obesity designed to assess CagriSema's "full weight-loss potential" with data expected in the first half of 2027. More intriguingly, Novo plans to start a phase 3 trial of higher-dose CagriSema (2.4 mg cagrilintide / 7.2 mg semaglutide) in the second half of 2026 -- tripling the semaglutide component. Novo's CEO pointed out that standard Wegovy doses produce 15-16% weight loss while the high dose reaches roughly 21%, suggesting meaningful room for improvement with a higher-dose CagriSema formulation.
REDEFINE 3 is the trial with the broadest long-term implications. It is an event-driven cardiovascular outcomes trial enrolling 7,000 adults with established cardiovascular disease. If CagriSema demonstrates cardiovascular benefits similar to what semaglutide showed in the SELECT trial, it could substantially expand the drug's prescribing indications and insurance coverage.
For patients waiting to access CagriSema, the realistic timeline is: if all goes smoothly with the FDA review, prescriptions could begin in late 2026 or early 2027. Insurance coverage and pricing remain unknowns, but CagriSema will enter a market where payer coverage for obesity drugs has been expanding steadily thanks to the cardiovascular evidence established by Wegovy.
The side effect profile: what 3,400 patients taught us
CagriSema's side effect profile will feel familiar to anyone who has taken a GLP-1 drug. The pattern is the same -- gastrointestinal issues dominate -- but the numbers are somewhat higher than semaglutide alone, which is expected when you combine two drugs that both affect the gut.
In REDEFINE-1, 79.6% of CagriSema patients experienced gastrointestinal adverse events, compared to 39.9% on placebo. The breakdown: nausea affected 55% of CagriSema patients (vs 12.6% placebo), constipation 30.7% (vs 11.6%), and vomiting 26.1% (vs 4.1%). The descriptor "mainly transient and mild-to-moderate" appears in both the NEJM abstract and Novo's press materials. Dr. Melanie Davies confirmed that "Everything was in line with what we expected."
| Side Effect | CagriSema | Placebo |
|---|---|---|
| Any GI adverse event | 79.6% | 39.9% |
| Nausea | 55.0% | 12.6% |
| Constipation | 30.7% | 11.6% |
| Vomiting | 26.1% | 4.1% |
| Discontinuation due to AEs | 5.9% | 3.5% |
| Serious adverse events | 6.3% | -- |
The discontinuation numbers provide the most useful safety signal. Only 5.9% of CagriSema patients left the trial due to adverse events, versus 3.5% on placebo. In REDEFINE-2 (the type 2 diabetes trial), the rate was higher at 8.4% versus 3%. Serious adverse events occurred in 6.3% of CagriSema patients. These rates are consistent with the broader GLP-1 receptor agonist class.
One legitimately open question concerns dose escalation. Fewer than two-thirds of patients progressed to the highest dose after 68 weeks, which investors flagged as a tolerability concern. But the clinical data complicates that interpretation. Novo's development chief Lange told Reuters that patients given lower doses often lost as much weight as those given higher doses, suggesting the need for flexible dosing schedules with longer intervals between dose increases rather than a rigid push to maximum dose.
The side effects are real and frequent, but they follow a pattern that clinicians who prescribe GLP-1 drugs already know how to manage. Most gastrointestinal symptoms diminish over time as the body adjusts. The low discontinuation rate -- under 6% -- suggests that for the vast majority of patients, the side effects are tolerable enough to continue treatment. The challenge for CagriSema will be whether patients and physicians see sufficient additional benefit over existing drugs to justify a somewhat higher GI symptom burden during the titration period.
Frequently Asked Questions
Is CagriSema better than Wegovy or Zepbound?
CagriSema produced more weight loss than semaglutide (Wegovy's active ingredient) alone in head-to-head comparisons within REDEFINE-1: 22.7% versus 16.1% on the on-treatment analysis. Against tirzepatide (Zepbound) in the REDEFINE-4 head-to-head trial, CagriSema produced 23% weight loss versus tirzepatide's 25.5% at 84 weeks. CagriSema is a clear step up from Wegovy but did not match Zepbound in direct comparison. However, its different mechanism (targeting amylin instead of GIP) may offer distinct benefits that weight-loss numbers alone do not capture.
When will CagriSema be available to patients?
Novo Nordisk filed for FDA approval in December 2025. A decision is expected in late 2026, with a potential launch in late 2026 or early 2027 if approved. European regulatory submission timelines have not been publicly disclosed.
What are the most common side effects of CagriSema?
Gastrointestinal side effects are the most common, with 55% of patients reporting nausea, 30.7% constipation, and 26.1% vomiting in the REDEFINE-1 trial. These were mostly transient and mild-to-moderate. About 5.9% of patients discontinued treatment due to side effects.
Does CagriSema help with conditions beyond weight loss?
Yes. REDEFINE-1 sub-analyses showed significant blood pressure reductions (systolic BP down 10.9 mmHg vs 2.8 mmHg placebo), and REDEFINE-2 showed 73.5% of patients reaching HbA1c targets for blood sugar control. A cardiovascular outcomes trial (REDEFINE 3) involving 7,000 patients is ongoing.
How is CagriSema different from other weight loss drugs in development like retatrutide?
CagriSema combines GLP-1 with amylin, while retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors. These are fundamentally different pharmacological strategies. CagriSema's amylin component may offer unique benefits in fat-selective weight loss and lean mass preservation, though this remains under investigation. Retatrutide showed about 24% weight loss in phase 2 trials but phase 3 results are pending.
Medical Disclaimer
This article is for informational and educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare professional regarding any medical concerns. Never ignore professional medical advice or delay seeking care because of something you read on this site. If you think you have a medical emergency, call 911 immediately.
